Reporting owner · CIK 0001221590
Bienaime Jean Jacques
Visual SEC Form 4 history across 2 companies, 6 transactions and 3 filings.
DIRAscendis Pharma A/S
Open-market mix
100%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
For every open-market buy (Form 4 code P, acquisition A) in the selected window, we take the closing price on the transaction date and 90 calendar days later, then compute the percentage change. The figures shown are the simple average and median of those per-buy returns.
- Window follows the rest of the summary (all-history or last 3 months).
- Only buys with a resolved price context are counted.
- Includes both positive and negative outcomes; gains and losses net out at the per-buy level.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
May 26
$95.1K
Jun 26
$0
Aug 26
$492.7K
Transaction texture
Ownership and ticket size
Average P/S size$146.9K
Median P/S size$135K
Direct6
Indirect0
Aug 14, 2026buy
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest sale
No open-market insider sale is available.
Associated companies
Visual map of known reporting history
| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 900 | $22.2M | P | +0.2% | 08/19 | 08/14 | |
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 1.10k | $27.0M | P | +0.2% | 08/19 | 08/14 | |
| KROS | BIENAIME JEAN JACQUES | DIR | grant | 7.43k | $0 | A | +10.8% | 06/05 | 06/03 | |
| KROS | BIENAIME JEAN JACQUES | DIR | grant | 7.14k | $0 | A | +10.8% | 06/05 | 06/03 | |
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 200 | $4.78M | P | +7.5% | 05/27 | 05/26 | |
| ASND | BIENAIME JEAN JACQUES | DIR | buy | 200 | $4.72M | P | +7.5% | 05/27 | 05/26 |
Bienaime Jean Jacques Insider Activity FAQ
SEC Form 4 context
Who is Bienaime Jean Jacques?
Bienaime Jean Jacques is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001221590.
Which companies has Bienaime Jean Jacques reported transactions for?
Ascendis Pharma A/S, Keros Therapeutics, Inc.
When was Bienaime Jean Jacques's latest insider buy?
buy at Ascendis Pharma A/S on Aug 14, 2026 valued at $222,219.
When was Bienaime Jean Jacques's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.